328 Index Name Paper ref. Name Paper ref. Durán, ST Mon 288, Thu 115, Tue 302 Dureau-Pournin, C Mon 145, Mon 132 Duret, J-P Mon 202 Durman, DK Mon 199 Durnev, A Tue 276 Durnev, AD Tue 165 Durroux, T FC11.3.5 Duruewuru, K Mon 017 Dusting, G Mon 194, FC06.4.5, Wed 219, FC15.2.5 Dutta, S Tue 453 Duty, S Wed 044 Duvauchelle, T Mon 201 Dygai, A Tue 167 Dyhring, T YI.10 Dykhal, YI Wed 175 Dyr, W Thu 174 Dyve, S FC17.4.5 Dzirkale, Z Wed 045 Eandi, M Wed 154 Eandi, M Mon 223 Eap, CB Tue 166, Mon 160 Ebeid, F Tue 386 Ebner, K W33.5 Ebrahimi, R Mon 202 Ebrahimi, SM Mon 188 Echeazarrra, L Wed 046 Echeverría, O Mon 176 Echizen, H Tue 486 Eden, T Tue 353 Edington, A Mon 052 Edlert, M Mon 371 Edvinsson, L Mon 450, Tue 185, Tue 220, Thu 239, Tue 298, Wed 021, Wed 033, Wed 213, Wed 292, Thu 053, Thu 056, Thu 066 Edwankar, RV FC03.3.3 Edwards, B W32.3 Edwards, G FC15.2.1, Wed 238 Edwards, R FC02.2.4 Eftekhari, A Mon 200, Thu 234 Eftekhari, S Wed 292 Egashira, N Mon 093, Thu 109 Egea, J Tue 042 Egutchi, S Thu 261 Eichelbaum, M Wed 133 Eidne, KA Wed 079 Eiermann, B Mon 371 Ejtemaei Mehr, S Thu 180 Ekici, H Wed 312 Ekokoski, E Tue 433 Ekström, L Thu 256, Wed 183, FC14.1.6, Wed 176 El Deeb, K Mon 282 El jebari, H FC07.3.6 El Saghir, N FC01.3.4 El-Banna, H Mon 016 El-Bassossy, H Mon 164, Mon 165 El-denshary, ES Tue 451 Elekes, K W19.3, Mon 283, Tue 271, Tue 250, Elgabarty, H FC06.2.6 El-Gendy, AAM Mon 340 Elgharbi, A Mon 290, Mon 377 Elhwuegi, A Wed 405 Eliasson, E FC13.4.5, Thu 256, Tue 318, Tue 138 Elie, V FC10.5.5 Elie, Valery Wed 011 Elies, J Wed 227 Elisabeth, S-G Tue 190 Elisabetsky, E FC16.2.3 Eliseeva, E Mon 133, Mon 134 Elkarimi, H Mon 378 El-Kiweri, I Mon 053 El-Lakkany, N Tue 386, Mon 372 Elliot, D Wed 124 Ellis, EM Mon 413 El-Maadawy, W Tue 386 El-Mallah, A Tue 264 Elmedal Laursen, B Wed 281, Wed 240 El-Moselhy, M Mon 164, Wed 441 Eloranta, JJ Thu 435 El-Yacoubi, M FC17.2.5 El-Yazbi, A Wed 239 Elzinga, CRS Wed 095 Elzorba, H Mon 016 Emami, A Tue 389 Emami, SA Thu 313 Embil, K Tue 142 Engelstoft, MS Thu 036 Enggaard, TP FC13.5.5 Engidawork, E FC01.2.5 Engström Hellgren, K Tue 308 Enwere, O Mon 017 Enzaka, J Mon 304 Epstein, D FC14.3.4 Epstein, OI Mon 198, Mon 284, Thu 015 Erb, C FC18.3.5 Ercanlý, T Tue 029 Erdeljic, V FC01.3.7, Mon 135, Mon 373, Tue 328 Erden, F Thu 401 Erdozain, AM Wed 031 Erenmemisoglu, A Tue 018 Ergüden, J Thu 091 Eriksson, L Tue 383 Eriksson, M Wed 006 Erin, N Mon 285 Erlendsson, S Tue 053 Erlinge, D Thu 074, Wed 052, Wed 062 Ermakov, S Tue 196 Ernst, G Mon 245 Eroglu, E Tue 031 Erol, A Thu 233 Erol, K Mon 103, Wed 406, Wed 420, Wed 421 Eromon, A Wed 369 Eromosele, S Mon 241 Ertoy Baydar, D Wed 253 Eruanga, V Mon 241 Esaki, Y Tue 260, Tue 294 Eschalier, A Thu 083 Escobar, L Mon 136, Tue 164, Tue 326 Escobar, T Mon 480 Escolano, L Mon 374, Tue 121, Wed 226, Thu 217
Name Paper ref. Name Paper ref. Escubedo, E Wed 174, Wed 177, Wed 181, Thu 179 Esen, AA Tue 200 Eskildsen, T FC06.2.5 Eskildsen-Helmond, Y Wed 240, Wed 241 Esmaeili, J Mon 454 Espino, J Mon 407 Esposito, E FC18.1.5, FC18.3.6, Mon 277, Mon 286 Esposito, G Tue 465, FC18.4.6 Esposti, ED Mon 120 Esposti, LD Mon 120 Esteban, A Thu 235 Esteves Pinto, C Wed 114, Thu 398 Estrada, S Wed 068 Estupiñan, J Mon 480 Eto, B Tue 040 Etter, M Mon 160 Euikyung, K Tue 017 Evangelista, JSAM Thu 374 Evans, A Wed 124, Tue 495 Evans, B Wed 063, Mon 395, Thu 059 Evans, C FC14.1.3 Evans, SJW FC04.2.3, FC04.3.2 Evans, W E FC13.2.4 Evcim, AS Tue 200 Exintaris, B Mon 240, Mon 242, Mon 248, Tue 416 Eyakem, AH Mon 018 Eybl, V Mon 409 Ezenwanebe, K Wed 296 Ezeokoli, CD Thu 326 Faal, M FC17.2.6 Fabio, B Thu 400 Fadda, E Tue 133 Faddah, LM Mon 189 Faghih Mirzaei, E Wed 376 Fagni, L FC11.3.3 Fago, A Wed 230 Fagundes, C W31.4 Fahmy, A Mon 165 Faiad, OJ Mon 273 Fakhoury, M FC10.1.5, Wed 011 Fakhrjou, A Tue 223 Falahi, G Thu 005 Falahpour, M Thu 005 Falcão, A Thu 169, Mon 383, Tue 407 Falcão, S Thu 366 Falk, E Wed 241 Falkay, G Mon 208, Mon 261, Wed 050, Wed 101 Falkbring, S Wed 092 Fameli, N Thu 264 Fan, D Tue 286 Fan, GW Wed 242 Fan, J FC15.2.5 FAN, L Tue 419 Fan, L Wed 257 Fan, S-J Thu 277 Fan, T-P FC16.4.1, Wed 330 Fan, X Tue 117 Fan, Y Tue 069 Fang, C Tue 399 Fang, C-K Wed 430 Fang, H Tue 138, Mon 458 Fang, L-H Wed 346 Fang, S Mon 457, Mon 458 Fang, SF Mon 325, Tue 317 Fantozzi, R Tue 256, Thu 434 Farar, V Thu 039 Farker, K Wed 119, Tue 131 Farooqi, S FC11.4.3 Farre, M Thu 177, Thu 178, Mon 137, Mon 109, Mon 375 Faruque, R Tue 097, Tue 120 Fätkenheuer, G Mon 315 Fauler, M FC12.2.3 Faure García, R Thu 347 Favaloro, JL Wed 288, Wed 289 Fawcett, K Mon 161 Fazekas, K Wed 423 Fazni, R Thu 181 Fazzi, G Thu 251 Fedorenko, A Mon 431 Fedotova, Y FC17.1.6, Wed 407, Wed 347 Feinshtein, V Mon 054 Feizi, I Thu 311 Felder, CC Thu 041 Feldkötter, M Thu 018 Feldman, BJ Wed 079 Feldman, M FC09.2.1 Félétou, M Thu 273, Thu 274 Félétou, Ml FC15.3.1 Felino, A Tue 261 Felix, AMR Mon 010 Fellman, V Thu 008 Feltner, D Wed 193 Fendt, A Wed 185 Feng, J Wed 267 Feng, L Mon 457, Mon 458, Tue 138 Feng, N Mon 466 Fennell, T Thu 021 Fenner, K Mon 236 Fenwick, P Tue 269 Feoktistova, Y Mon 133 Ferchichi, H Thu 346, Wed 348, Mon 004 Ferk, Polonca Wed 178 Fernandes, AC Mon 276 Fernandes, D Wed 097, Wed 251, Thu 064 Fernandes, ES Mon 287 Fernandes, K W01.2.4 Fernandes, LGR Mon 289 Fernandes, MA Wed 045 Fernandes, MH Tue 261 Fernandes, P Thu 204 Fernández Lima, O Wed 311, Thu 347 Fernández, H Thu 205 Fernandez, MC Tue 123, Wed 109 Fernández, N Wed 224 Fernández-Arche, MA Tue 409, Wed 349 Fernandez-Aviles, F W09.5 Fernández-Llimós, F Mon 376 Fernandez-Morales, JC FC16.2.5, FC12.1.6 Fernández-Pérez, L Tue 387, Tue 391, Tue 392 Fernandez-Vallin, E Wed 209 Ferrand, N Thu 055 Ferrante, C Mon 105, Wed 434, Wed 329 Ferreira, EB Tue 101 Index 329
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281: W34 State-of-the-art of basic and c
- Page 282 and 283: FC10 Drugs for half the world: Paed
- Page 284 and 285: FC11 G protein-coupled 7TM receptor
- Page 286 and 287: FC11 G protein-coupled 7TM receptor
- Page 288 and 289: FC11 G protein-coupled 7TM receptor
- Page 290 and 291: FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381:
378 Index Name Paper ref. Name Pape
- Page 382 and 383:
380 Index Name Paper ref. Name Pape
- Page 384 and 385:
382 Notes Notes
- Page 386:
Final Programme printed in Singapor